Korea University College of Medicine

A Comparative Analysis of Two SARS-CoV-2 Vaccines: Insights from Korea University College of Medicine

Retrieved on: 
Thursday, November 9, 2023
AS03, Infection, Vaccine, SARS-CoV-2, Korea University College of Science, Safety, Injection, Research, Clinical trial, COVID-19, Messenger, GBP510, Korea University College of Medicine, Pharmaceutical industry

SEOUL, South Korea, Nov. 9, 2023 /PRNewswire/ -- GBP510, a recombinant vaccine against COVID-19, adjuvanted with AS03, has shown to be highly immunogenic and well tolerated in healthy adults. Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. Interim results show that GBP510/AS03 had an acceptable safety profile and induced stronger antibody responses when compared with ChAdOx1-S.

Key Points: 
  • Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine.
  • Interim results show that GBP510/AS03 had an acceptable safety profile and induced stronger antibody responses when compared with ChAdOx1-S.
  • The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019.
  • Since then, extensive efforts have been made to develop and evaluate vaccines to combat the virus.

Seoul Viosys Announces That Violeds Sterilizes Omicron Variant As Well

Retrieved on: 
Monday, February 14, 2022
Semiconductor, Other Transport, Manufacturing, Other Health, Environment, Retail, Transport, Automotive, Building Systems, Infectious Diseases, Hardware, Technology, Construction & Property, Restaurant, Bar, Health, Other Manufacturing, Other Automotive, University, Education, KOSDAQ, Risk, Infection, Nitride, NS, VAC, CES, Atmosphere, Seti, Solution, Viol, Smartphone, Seoul Semiconductor, No, Korea University College of Science, Korea University College of Medicine, RGB, Environment, Horticulture, Technology, Omicron, Virus, Disinfectant, El Garces Intermodal Transportation Facility, Facial recognition, Bacteria, Ultraviolet, Car, Korea University, 3D, Growth, Research, Multimedia, Severe acute respiratory syndrome coronavirus 2, COVID-19, Restaurant, Vertical-cavity surface-emitting laser, Sterilization, Infrared, UV, Television, Medical device, Delta, VCSEL

Seoul Viosys (KOSDAQ: 092190), a company specializing in optical semiconductors, announced an experimental result confirming that its Violeds technology sterilizes 99.99% Omicron Variant (SARS-CoV-2 Variant: B.1.1529) in one second, which has been spreading around the world.

Key Points: 
  • Seoul Viosys (KOSDAQ: 092190), a company specializing in optical semiconductors, announced an experimental result confirming that its Violeds technology sterilizes 99.99% Omicron Variant (SARS-CoV-2 Variant: B.1.1529) in one second, which has been spreading around the world.
  • View the full release here: https://www.businesswire.com/news/home/20220213005104/en/
    Omicron virus sterilization test using Violeds technology, Seoul Viosys (Graphic: Business Wire)
    Seoul Viosys conducted the Omicron sterilization test at the Virology Research Institute of Korea University College of Medicine, and it was confirmed that the Omicron virus exposed to the Violeds LED was sterilized 99.99% in only one second.
  • Seoul Viosys has been conducting various sterilization experiments using its Violeds technology since 2019.
  • Seoul Viosys' bio research team released research data that the air purifying sterilizer with Violeds technology applied could lower the risk of airborne infection by one-thirtieth.

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, September 1, 2021
SingHealth, Oregovomab, Terminology, Ovarian cancer, Drug combination, Korea University College of Science, PD-1, KOREA, Paclitaxel, Korean Government Scholarship Program, Cancer, Carboplatin, Korea University College of Medicine, Doxorubicin, Survival, HER2/neu, Bevacizumab, MUC1, PSA, Disease, Platinum, Gynecologic Oncology (journal), Death, TSX Venture Exchange, Antibody, Clinical trial, Overalls, Safety, Risk, Cancer immunology, Patient, Immunoglobulin G, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Toxicity, Immunization, Hospital, Nivolumab, Pharmaceutical industry

The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583).

Key Points: 
  • The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583).
  • The second study(ORION-02), led by Clinical Assistant Professor Jack Chan, is being conducted at a single centre in Singapore (National Cancer Centre Singapore).
  • OncoQuest has completed a Phase II study using oregovomab in combination with a TLR-3 agonist (Hiltonol) in the recurrent ovarian cancer setting (ClinicalTrials.gov Identifier: NCT03162562).
  • OncoQuest is also in the process of initiating a clinical trial using oregovomab with niraparib in the recurrent ovarian cancer setting.